Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira®in healthy subjects

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 983-993

  Hyland, Elizabeth ^a   Mant, Tim ^b   Vlachos, Pantelis ^c   Attkins, Neil ^d   Ullmann, Martin ^e   Roy, Sanjeev ^f   Wagner, Volker ^a  

^a Clinical Development   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Cytel Inc   (Switzerland)

^d PAREXEL INTERNATIONAL   (United States)

^e Merck Biosimilars   (Switzerland)

^f Analytical and Pharmaceutical Development   (Switzerland)

Author keywords

adalimumab; biosimilar; pharmacokinetics; safety

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; MSB 11022; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNITED STATES;

EID: 84986253535     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13039     Document Type: Article

References (15)

1. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo-controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29: 2288–98.
2. Humira (adalimumab) injection, for subcutaneous use. North Chicago, IL: AbbVie Inc., September 2015 [online]. http://www.rxabbvie.com/pdf/humira.pdf (last accessed 11 December 2015).
3. SPC. Humira pre-filled pen, pre-filled syringe and vial. Maidenhead, UK: Abbvie Ltd, November 2015 [online]. Available at https://www.medicines.org.uk/emc/medicine/21201 (last accessed 11 December 2015).
4. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517–24.
5. Benucci M, Li Gobbi F, Meacci F, Manfredi M, Infantino M, Severino M, et al. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics 2015; 9: 7–12.
6. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921–6.
7. FDA Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), April 2015 [online]. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (last accessed 11 December 2015).
8. European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK: European Medicines Agency, May 2012 [online]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf (last accessed 11 December 2015).
9. Magnenat L, Palmese A, Fremaux C, D'Amici F, Terlizzese M, Rossi M, et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. mAbs 2016; Manuscript submitted.
10. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104–9.
11. van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem 2014; 289: 34482–8.
12. Thomas SS. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015; 29: 241–58.
13. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244–79.
14. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819–36.
15. Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of long-term data. J Rheumatol 2011; 38: 1552–62.